Perhaps already best positioned in the competitive FGF21 analog class in non-alcoholic steatohepatitis development, 89bio, Inc. bolstered its positioning with a late-breaker presentation on 12 November at the American Association for the Study of Liver Disease meeting with subgroup analysis from its successful Phase IIb study of pegozafermin showing that the weekly injectable drug might offer fibrosis benefit in the sickest patients, those with cirrhosis (F4 fibrosis).
Key Takeaways
-
89bio presented Phase IIb subgroup analysis at the AASLD conference suggesting a fibrosis-reduction benefit for pegozafermin in cirrhotic NASH patients.
89bio is competing primarily with Akero Therapeutics, Inc. and its Phase II efruxifermin and privately held Boston Pharmaceuticals...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?